MIR126

Summary

MIR126 (microRNA 126, HGNC:31508) is a microRNA gene on chromosome 9q34.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406913 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31508
Approved symbol	MIR126
Name	microRNA 126
Location	9q34.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-126
Ensembl gene	ENSG00000199161
Ensembl biotype	miRNA
OMIM	611767
Entrez	406913
RNAcentral	URS0000759B6D — miRNA, 85 nt, 4 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362291

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362291 — 1 exons

Exon	Start	End
ENSE00001437054	136670602	136670686

Expression profiles

Bgee: expression breadth ubiquitous, 109 present calls, max score 99.87.

Top tissues by expression

109 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
placenta	UBERON:0001987	99.87	gold quality
renal glomerulus	UBERON:0000074	96.51	gold quality
skeletal muscle tissue	UBERON:0001134	93.64	gold quality
epididymis	UBERON:0001301	93.10	gold quality
apex of heart	UBERON:0002098	93.09	gold quality
endometrium	UBERON:0001295	89.57	gold quality
muscle of leg	UBERON:0001383	85.27	gold quality
right lung	UBERON:0002167	84.68	gold quality
heart left ventricle	UBERON:0002084	82.84	gold quality
sural nerve	UBERON:0015488	82.62	gold quality
duodenum	UBERON:0002114	81.55	gold quality
adrenal tissue	UBERON:0018303	81.26	gold quality
heart	UBERON:0000948	81.10	gold quality
uterus	UBERON:0000995	80.98	gold quality
right atrium auricular region	UBERON:0006631	80.58	gold quality
myometrium	UBERON:0001296	80.54	gold quality
bone marrow	UBERON:0002371	79.93	gold quality
spleen	UBERON:0002106	79.36	gold quality
lung	UBERON:0002048	79.34	gold quality
vermiform appendix	UBERON:0001154	78.89	gold quality
upper lobe of left lung	UBERON:0008952	78.53	gold quality
adult mammalian kidney	UBERON:0000082	74.98	gold quality
blood	UBERON:0000178	74.85	gold quality
islet of Langerhans	UBERON:0000006	74.31	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	74.14	gold quality
omental fat pad	UBERON:0010414	73.83	gold quality
kidney	UBERON:0002113	73.70	gold quality
right adrenal gland cortex	UBERON:0035827	73.61	gold quality
body of stomach	UBERON:0001161	73.47	gold quality
stomach	UBERON:0000945	73.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.95

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETS2, NSD2

Literature-anchored findings (GeneRIF, showing 40)

• Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype. (PMID:18193184)
• Endothelial cells express microRNA 126 (miR-126), which inhibits VCAM-1 expression. (PMID:18227515)
• miR-126 may function in normal hematopoietic cells to modulate HOXA9 protein. (PMID:18474618)
• Over-expression of miR126 in a lung cancer cell line resulted in a decrease in Crk protein without any alteration in the associated mRNA. (PMID:18602365)
• miR-126 regulates PI3K signaling partly by targeting p85beta, and loss of miR-126 may provide a selective growth advantage during colon carcinogenesis. (PMID:18663744)
• miR-126 regulates PI3K signaling partly by targeting p85beta, and that the loss of miR-126 may provide a selective growth advantage during colon carcinogenesis. (PMID:18663744)
• miRNA 17-5p, 20a and 126 are constitutively expressed in Ph(-) MPN megakaryopoiesis while low or absent miRNA 10a appeared to correlate with strong megakaryocytic HOXA1 protein expression (PMID:18773208)
• mir-126, a cell growth suppressor, targets IRS-1. (PMID:18834857)
• Mature miR-126 can be generated from three different transcripts of EGFL7 with each one having its own promoter. (PMID:19116145)
• inhibits growth of lung cancer cells (PMID:19223090)
• miR-126 can inhibit proliferation of non-small cell lung cancer cells through one of its targets, EGFL7. (PMID:20034472)
• MiR-126 is highly expressed in the lung; MiR-126 downregulation in cystic fibrosis (CF) bronchial epithelial cells correlates with a significant upregulation of target of Myb(TOM)1 messenger RNA. (PMID:20083669)
• miR-126 can downregulate EGFL7 expression at the protein level in ECV-304 cells. (PMID:20423846)
• miR-126 was significantly down-regulated in gastric cancer tissues and was associated with clinicopathological features, including tumour size, lymph node metastasis, local invasion and tumour-node-metastasis stage. (PMID:20619534)
• miR-126 SNP significantly blocks the processing of pri-miRNA to mature miRNA, as well as reduces miRNA-mediated translational suppression. (PMID:20621067)
• Plasma miR-126 is reduced in vascular endothelium of type 2 diabetes mellitus patients. (PMID:20651284)
• transcription factors Ets-1 and Ets-2 play a key role in controlling the expression of miR-126 and suggest that miR-126 may mediate some of their vascular effects (PMID:20671229)
• miR-126 may be a novel suppressive microRNA (PMID:20680522)
• Studies indicate that two biologically active miRNAs miR-126 and its complement miR-126*, which are encoded by intron 7 of the egfl7 gene, have been described to mediate vascular functions. (PMID:20953557)
• our data suggest that the two genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. (PMID:21046227)
• Downregulation of MIR126 is associated with parathyroid tumors. (PMID:21086055)
• important function of miRs-126/126* in negative regulation of erythropoiesis, providing the first evidence for a role of miR in hematopoietic differentiation of embryonic stem cells (PMID:21163928)
• miR-126 could target both VEGFA and PIK3R2, and its expression was decreased in human breast cancer, implying that miR-126 may play a role in tumor genesis and growth by regulating the VEGF/PI3K/AKT signaling pathway (PMID:21249429)
• miR-126 is a strong and independent negative prognostic factor in NSCLC, and its prognostic impact appears related primarily to histology and nodal status. (PMID:21264844)
• hsa-miR-126 and hsa-miR-518b are differentially expressed in esophageal squamous carcinoma, and might play important roles in carcinogenesis and progression. (PMID:21269950)
• miR-126 is a novel miRNA that targets SOX2, and PLAC1 may be a novel downstream target gene of SOX2 in gastric cancer cells. (PMID:21304604)
• Data shwo that SLC7A5 is a direct target of miR-126. (PMID:21439283)
• miR-126 was actively involved in the development of insulin resistance induced by mitochondrial dysfunction. (PMID:21464990)
• miR-126, in association with soluble mesothelin-related peptides, as a marker for early detection of malignant pleural mesothelioma (PMID:21483773)
• MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1(+)/Lin(-) progenitor cells in ischaemia. (PMID:21856785)
• miR-126 may play an initial role in the development and progression of EMs. Crk may be regulated by miR-126, and synergism between abnormal expressions may play an important role in the pathogenesis of EMs. (PMID:22012249)
• The miR-126/ADAM9 axis plays essential role in the inhibition of invasive growth of pancreatic cancer cells. (PMID:22064652)
• endogenous miR-126, an miRNA silenced in a variety of common human cancers, non-cell-autonomously regulates endothelial cell recruitment to metastatic breast cancer cells, in vitro and in vivo (PMID:22170610)
• enhanced expression of miR-126 suppressed the growth of A549 xenograft and inhibited the expression of VEGFA and MRP1. (PMID:22510476)
• miR-126 is downregulated in endothelial progenitor cells (EPCs) from diabetic patients. (PMID:22525256)
• Neovascularization is induced in duodenal tissue of patients with cirrhosis and proangiogenic factors such as KLF-2, Ang-2, miR-126 and VEGF can contribute to the angiogenesis induced by hemodynamic forces. (PMID:22574900)
• expression of miR-126 correlated with integrin, alpha-X (ITGAX) mRNA levels (a gene specific for proinflammatory [M1] macrophages), regardless of body fat mass (PMID:22688341)
• Results suggest that the plasma concentrations of miR-1 and miR-126 may be useful indicators for AMI. (PMID:22719221)
• MicroRNA-126 down-regulation is associated with increased VCAM-1 in both muscle and blood in dermatomyositis. (PMID:22740338)
• miR-126-mediated phosphoinositide-3-kinase regulation, not only fine-tunes VEGF-signaling, but it strongly enhances the activities of Ang-1 on vessel stabilization and maturation. (PMID:22867989)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir126a	ENSDARG00000081476
danio_rerio	mir126b	ENSDARG00000098981
mus_musculus	Mir126a	ENSMUSG00000065540

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.